ConditionsNCT07524933
Comparison of the Effectiveness of Nerve Hydrodissection With Saline Injection of 5% Dextrose in Carpal Tunnel Syndrome.
A study testing Nerve Hydrodissection with 5% Dextrose in people with Conditions, run by Antalya Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Comparison of the effectiveness of nerve hydrodissection with saline injection of 5% dextrose in carpal tunnel syndrome. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Conditions
- What is being tested?
- Nerve Hydrodissection with 5% Dextrose
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 96 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 8 Jan 2026to 10 Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adults aged 18-80 years
- Clinical and electrophysiological diagnosis of mild to moderate carpal tunnel syndrome
- Symptom duration of at least 3 months
- Both male and female participants
- Patients who have not responded adequately to conservative treatment
- Patients who do not wish to undergo surgical treatment
- Ability to provide informed consent
Who cannot join
- Severe or very severe carpal tunnel syndrome based on EMG findings
- Previous injection therapy for carpal tunnel syndrome
- Prior wrist or carpal tunnel surgery
- Polyneuropathy or other peripheral neuropathies
- Cervical radiculopathy or proximal median nerve entrapment
- Brachial plexopathy or thoracic outlet syndrome
Show all 11Show fewer
- Pregnancy
- Malignancy
- Local or systemic infection
- Cognitive impairment affecting cooperation
- Systemic diseases affecting the median nerve (e.g., uncontrolled diabetes mellitus, thyroid disorders)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of Pain, Hand Function, Electrophysiological and Ultrasonographic Effects When Comparing 5% Dextrose Saline Injection Via Nerve Hydrodissection Under Ultrasound Guidance in Mild to Moderate Carpal Tunnel Syndrome.
Comparison of the effectiveness of nerve hydrodissection with saline injection of 5% dextrose in carpal tunnel syndrome.
Read the detailed description
Evaluation of pain, hand function, electrophysiological and ultrasonographic effects when comparing 5% dextrose saline injection via nerve hydrodissection under ultrasound guidance in mild to moderate carpal tunnel syndrome.
- Conditions
- Conditions
- Being tested
- Nerve Hydrodissection with 5% Dextrose
- Medical subject headings
- Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nerve Hydrodissection with 5% DextroseDrug
Also called Saline Injection (Placebo / Sham), Splint group
Injection therapy
| Study group | Role | What they receive |
|---|---|---|
| 5% dextrose group | Active comparator | Ultrasound-guided median nerve hydrodissection with 5% dextrose Receives: Drug: Nerve Hydrodissection with 5% Dextrose |
| Saline group | Sham comparator | Sham ultrasound-guided perineural injection with normal saline Receives: Drug: Nerve Hydrodissection with 5% Dextrose |
| Splint group | Sham comparator | Patients use only a wrist splint without injection therapy Receives: Drug: Nerve Hydrodissection with 5% Dextrose |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in pain intensity measured by Visual Analog Scale (VAS)
The primary outcome is the change in pain intensity assessed by the Visual Analog Scale (VAS, 0-10). The difference between baseline and follow-up scores will be analyzed.
Measured: Baseline to 8 month
Secondary outcomes (4)
Change in Qucik DASH score
Assessed using symptom severity and functional status scales
Measured: Baseline to 8 month
Change in median nerve cross-sectional area
Measured at the carpal tunnel inlet using ultrasonography
Measured: Baseline to 8 month
hange in nerve conduction study parameters
Distal motor latency and sensory conduction velocity of the median nerve
Measured: Baseline to 8 month
Change in hand grip strength
Strength of the arm
Measured: Baseline to 8 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start8 Jan 2026
- Primary completion10 Jul 2026 (estimated)
- Study completion10 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ConditionsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 96 participants (actual)
Sponsor and investigators
- Lead sponsor
- Antalya Training and Research Hospital
- Sponsor type
- Other government
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07524933
- Sponsor's protocol ID
- 2026528
- Status last verified
- Apr 2026
- First submitted
- 30 Mar 2026
- Last updated
- 13 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Pain, Hand Function, Electrophysiological and Ultrasonographic Effects When Comparing 5% Dextrose Saline Injection Via Nerve Hydrodissection Under Ultrasound Guidance in Mild to Moderate Carpal Tunnel Syndrome.
- ClinicalTrials.gov ID
- NCT07524933
- Acronym / sponsor ID
- 2026528
- Conditions
- Conditions
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 96 participants (actual)
- Lead sponsor
- Antalya Training and Research HospitalOther government
- Study start
- 8 Jan 2026 (actual)
- Primary completion
- 10 Jul 2026 (estimated)
- Study completion
- 10 Jul 2026 (estimated)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Comparison of the effectiveness of nerve hydrodissection with saline injection of 5% dextrose in carpal tunnel syndrome.
Detailed description
Evaluation of pain, hand function, electrophysiological and ultrasonographic effects when comparing 5% dextrose saline injection via nerve hydrodissection under ultrasound guidance in mild to moderate carpal tunnel syndrome.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 5% dextrose group | Active comparator | Drug: Nerve Hydrodissection with 5% DextroseUltrasound-guided median nerve hydrodissection with 5% dextrose |
| Saline group | Sham comparator | Drug: Nerve Hydrodissection with 5% DextroseSham ultrasound-guided perineural injection with normal saline |
| Splint group | Sham comparator | Drug: Nerve Hydrodissection with 5% DextrosePatients use only a wrist splint without injection therapy |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adults aged 18-80 years
- Clinical and electrophysiological diagnosis of mild to moderate carpal tunnel syndrome
- Symptom duration of at least 3 months
- Both male and female participants
- Patients who have not responded adequately to conservative treatment
Key exclusion criteria (11 listed)
- Severe or very severe carpal tunnel syndrome based on EMG findings
- Previous injection therapy for carpal tunnel syndrome
- Prior wrist or carpal tunnel surgery
- Polyneuropathy or other peripheral neuropathies
- Cervical radiculopathy or proximal median nerve entrapment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nerve Hydrodissection with 5% DextroseAlso: Saline Injection (Placebo / Sham), Splint groupInjection therapy | Drug | 5% dextrose group, Saline group, Splint group |
Primary outcome
Change in pain intensity measured by Visual Analog Scale (VAS)
Time frame: Baseline to 8 month
The primary outcome is the change in pain intensity assessed by the Visual Analog Scale (VAS, 0-10). The difference between baseline and follow-up scores will be analyzed.
4 secondary outcomes
Change in Qucik DASH score
Time frame: Baseline to 8 month
Change in median nerve cross-sectional area
Time frame: Baseline to 8 month
hange in nerve conduction study parameters
Time frame: Baseline to 8 month
Change in hand grip strength
Time frame: Baseline to 8 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Conditions
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Not yet recruiting
Effect of Stress Ball Use During Femoral Arterial Sheath Removal After Coronary Angiography
Femoral Arterial Sheath Removal, Stress Ball
Not yet recruiting
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Aphasia (BG-Aphasia-01)
Expressive Aphasia, Aphasia Following Cerebral Infarction
Recruiting
Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area
Anastomotic Leaks, Hartmanns Stump Leakage
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nerve Hydrodissection with 5% Dextrose in people with Conditions, run by Antalya Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 13 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in pain intensity measured by Visual Analog Scale (VAS) (time frame: Baseline to 8 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Apr 2026.